title: Further evaluation of the use of buparvaquone in the infection and treatment method of immunizing cattle against Theileria parva derived from African buffalo (Syncerus caffer).
abstract: Three experiments were undertaken to determine the efficacy of different doses of buparvaquone in the infection and treatment immunization of cattle against Theileria parva derived from African buffalo (Syncerus caffer). Two of these experiments also compared buparvaquone with standard doses of long- and short-acting formulations of oxytetracycline. In addition, different dilutions of stabilates were used in the experiments. In the first experiment, a 10(-1.0) dilution of stabilate was used to infect groups of cattle treated with buparvaquone at doses of between 5 and 0.625 mg kg-1 body weight (bwt) on Day 0 after infection. All control cattle developed severe theileriosis and none of the treatment regimes (including those utilizing long-acting oxytetracycline) prevented the development of theileriosis. Treatment with buparvaquone at 2.5 mg kg-1 bwt or oxytetracycline gave the most satisfactory results. In the second experiment when the sporozoite dose was reduced to 10(-2.0) dilution, buparvaquone treatment at 5 and 2.5 mg kg-1 bwt and short- and long-acting formulations of oxytetracycline reduced reactions greatly. While all the oxytetracycline treated animals produced a serological response and were immune to a 50-fold higher challenge with the immunizing stabilate, several animals in the buparvaquone groups did not show a serological response and were not immune to challenge. In the third experiment, groups of cattle were infected with 10(-1.2), 10(-1.4) and 10(-1.6) dilutions of stabilate and were treated with 2.5 mg kg-1 bwt of buparvaquone. No animals developed severe theileriosis and all seroconverted. On homologous challenge, however, two out of 14 cattle showed severe reactions. It was concluded that further work on immunization using buparvaquone treatment at 2.5 mg kg-1 bwt and 10(-1.6) dilution of the stabilate would have to be carried out before such a system could be used in the field.
authors.affiliation: Protozoology Division, National Veterinary Research Centre, Muguga, Kenya.
authors.forename: P N
authors.initials: PN
authors.lastname: Ngumi
authors.forename: A S
authors.initials: AS
authors.lastname: Young
authors.forename: D
authors.initials: D
authors.lastname: Lampard
authors.forename: S K
authors.initials: SK
authors.lastname: Mining
authors.forename: S G
authors.initials: SG
authors.lastname: Ndungu
authors.forename: A C
authors.initials: AC
authors.lastname: Lesan
authors.forename: S M
authors.initials: SM
authors.lastname: Williamson
authors.forename: A
authors.initials: A
authors.lastname: Linyonyi
authors.forename: D P
authors.initials: DP
authors.lastname: Kariuki
mesh_terms: D000818:Animals; D000913:Antibodies, Protozoan / Q000097:blood; D000981:Antiprotozoal Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002020:Buffaloes / Q000469:parasitology; D002417:Cattle; D005069:Evaluation Studies as Topic; D007114:Immunization / Q000379:methods / Q000662:veterinary*; D009285:Naphthoquinones / Q000494:pharmacology / Q000627:therapeutic use*; D010118:Oxytetracycline / Q000627:therapeutic use; D016797:Theileria parva / Q000187:drug effects* / Q000276:immunology; D013801:Theileriasis / Q000188:drug therapy / Q000517:prevention & control*
chemical_list: D000913:Antibodies, Protozoan; D000981:Antiprotozoal Agents; D009285:Naphthoquinones; C046326:buparvaquone; D010118:Oxytetracycline